This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sarepta CEO: $125 Million Offering Demand Was Strong

BOSTON ( TheStreet) -- I chatted briefly by phone with Sarepta Therapeutics (SRPT) CEO Chris Garabedian following the successful follow-on stock offering that raised $125 million.

Here are some excerpts from our conversation:

On investor demand for the offering:

"We went out with a target of raising $75 million but by the time we were ready to close the book we were more than three times oversubscribed, almost four times... The book was full of top quality institutional investors, many of whom were not going to get the allocation they wanted, so we decided to upsize the offering."

On Sarepta's new shareholder base:

"Previously, we had about 35% institutional investors. With the close of this offering, we're up to 50%, including a lot of long-only accounts and good fundamental life-sciences investors. It's really nice to see the company's shareholder base change.

On the timing of the stock offering:

"It's hard to find the right financing window where we don't have disclosure issues... But we had the 62-week eteplirsen data behind us, investor demand was high and you always worry about macro risk so we decided to get an offering in before the end of the year. It's nice to enjoy the holidays knowing we have a very healthy balance sheet."

On plans for the FDA meeting to discuss the possibility of filing accelerated approval for eteplirsen:

"We're sticking with our guidance that we will be requesting a meeting with FDA before the end of the year, which puts us squarely on track to have the meeting in the first quarter."

When can investors expect to hear from Sarepta about the outcome of the FDA meeting?

"We won't be saying anything publicly until we get the final minutes from the FDA meeting, which probably means a March-April timeframe. At that point, we'll update investors on whether or not we will be pursuing an accelerated approval for eteplirsen. "

On eteplirsen manufacturing and timing of a possible eteplirsen approval filing:

"We need to have difference discussions with FDA about clinical and manufacturing issues. The plan right now is to meet with FDA about CMC chemistry, manufacturing and controls in the second quarter... How or when we file will be dictated by the outcome and feedback we get from FDA at both these meetings."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs